Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 20/20 | 0.54 |
| ▸ | AURKA | O14965 | 19/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14508085 | 0.90 | AURKB (0.47) | AURKBAURKA | |
| SCHEMBL12404635 | 0.84 | AURKB (0.65) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL14507582 | 0.83 | AURKB (0.43) | AURKBAURKACHEK1LCKRPS6KA3 | |
| SCHEMBL14507581 | 0.83 | AURKB (0.53) | AURKBAURKACHEK1KDRRPS6KA3 | |
| SCHEMBL14507605 | 0.78 | AURKA (0.40) | AURKBAURKACHEK1 | |
| SCHEMBL14507603 | 0.78 | AURKB (0.39) | AURKBAURKA | |
| SCHEMBL14536767 | 0.78 | TTK (0.40) | AURKBAURKACHEK1LCKRPS6KA3 | |
| SCHEMBL14536800 | 0.78 | AURKB (0.39) | AURKBAURKACHEK1KDRRPS6KA3 | |
| SCHEMBL14507591 | 0.78 | ANPEP (0.41) | AURKBAURKA | |
| SCHEMBL14507635 | 0.78 | PTK6 (0.41) | AURKBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | AURKB 138/4885AURKA 41/4885CHEK1 1/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | AURKB 24/4885AURKA 5/4885CHEK1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.